BioWorld-International-2006-08-09
Paion Accelerates Phase III Program For Desmoteplase
Paion Accelerates Phase III Program For Desmoteplase
Paion AG is accelerating the Phase III development program for its lead compound, the recombinant plasminogen activator Desmoteplase, which is in development for treating acute ischemic stroke. (BioWorld International)

